Skip to main content
Top
Published in: Journal of General Internal Medicine 4/2019

01-04-2019 | Original Research

Randomized Trial of Personalized Breast Density and Breast Cancer Risk Notification

Authors: Jennifer S. Haas, MD, MSc, Catherine S. Giess, MD, Kimberly A. Harris, MM, Julia Ansolabehere, Celia P. Kaplan, DrPh, MA

Published in: Journal of General Internal Medicine | Issue 4/2019

Login to get access

Abstract

Background

Despite widespread implementation of mammographic breast density (MBD) notification laws, the impact of these laws on knowledge of MBD and knowledge of breast cancer risk is limited by the lack of tools to promote informed decision-making in practice.

Objective

To develop and evaluate whether brief, personalized informational videos following a normal mammogram in addition to a legislatively required letter about MBD result can improve knowledge of MBD and breast cancer risk compared to standard care (i.e., legislatively required letter about MBD included with the mammogram result).

Design/Participants

Prospective randomized controlled trial of English-speaking women, age 40–74 years, without prior history of breast cancer, receiving a screening mammogram with a normal or benign finding (intervention group n = 235, control group n = 224). Intervention: brief (3–5 min) video, personalized to a woman’s MBD result and breast cancer risk.

Main Measures

Primary outcomes were a woman’s knowledge of her MBD and risk of breast cancer. Secondary outcomes included whether a woman reported that she discussed the results of her mammogram with her primary care provider (PCP).

Key Results

Relative to women in the control arm, women in the intervention arm had greater improvement in their knowledge of both their personal MBD (intervention pre/post 39.2%/ 77.5%; control pre/post 36.2%/ 37.5%; odds ratio (OR) 5.34 for change for intervention vs. control, 95% confidence interval (CI) 3.87–7.36; p < 0.001) and risk of breast cancer (intervention pre/post: 66.8%/74.0%; control pre/post 67.9%/ 65.2%; OR 1.42, 95% confidence interval (CI) 1.09–1.84; p = 0.01). Women in the intervention group were more likely than those in the control group to report discussing the results of their mammogram with their PCP (p = 0.05).

Conclusions

Brief, personalized videos following mammography can improve knowledge of MBD and personal risk of breast cancer compared to a legislatively mandated informational letter.
Trial Registration
Clinicaltrials.​gov (NCT02986360)
Appendix
Available only for authorised users
Literature
1.
go back to reference Smith RA, Kerlikowske K, Miglioretti DL, Kalager M. Clinical decisions. Mammography screening for breast cancer. N Engl J Med 2012;367:e31.CrossRefPubMed Smith RA, Kerlikowske K, Miglioretti DL, Kalager M. Clinical decisions. Mammography screening for breast cancer. N Engl J Med 2012;367:e31.CrossRefPubMed
2.
go back to reference Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL, Breast Cancer Surveillance C. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med 2015;162:673–81.CrossRefPubMedPubMedCentral Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL, Breast Cancer Surveillance C. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med 2015;162:673–81.CrossRefPubMedPubMedCentral
3.
go back to reference Porter GJ, Evans AJ, Cornford EJ, Burrell HC, James JJ, Lee AH, Chakrabarti J. Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol 2007;188:676–83.CrossRefPubMed Porter GJ, Evans AJ, Cornford EJ, Burrell HC, James JJ, Lee AH, Chakrabarti J. Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol 2007;188:676–83.CrossRefPubMed
4.
go back to reference Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, Wernli KJ, Miglioretti DL, O'Meara ES. Outcomes of Screening Mammography by Frequency, Breast Density, and Postmenopausal Hormone Therapy. JAMA Intern Med 2013:1–10. Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, Wernli KJ, Miglioretti DL, O'Meara ES. Outcomes of Screening Mammography by Frequency, Breast Density, and Postmenopausal Hormone Therapy. JAMA Intern Med 2013:1–10.
7.
go back to reference Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, Kerlikowske K, Miglioretti DL. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 2014;106. Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, Kerlikowske K, Miglioretti DL. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 2014;106.
8.
go back to reference Kressin NR, Gunn CM, Battaglia TA. Content, Readability, and Understandability of Dense Breast Notifications by State. JAMA 2016;315:1786–8.CrossRefPubMed Kressin NR, Gunn CM, Battaglia TA. Content, Readability, and Understandability of Dense Breast Notifications by State. JAMA 2016;315:1786–8.CrossRefPubMed
9.
10.
go back to reference Klinger EV, Kaplan CP, St. Hubert S, Birdwell RL, Haas JS. Patient and Provider Perspectives on Mammographic Breast Density Notification Legislation. MDM Policy & Practice 2017;1:1–8. Klinger EV, Kaplan CP, St. Hubert S, Birdwell RL, Haas JS. Patient and Provider Perspectives on Mammographic Breast Density Notification Legislation. MDM Policy & Practice 2017;1:1–8.
11.
go back to reference Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005;94:115–22.CrossRefPubMed Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005;94:115–22.CrossRefPubMed
12.
go back to reference Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148:337–47.CrossRefPubMedPubMedCentral Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148:337–47.CrossRefPubMedPubMedCentral
13.
go back to reference Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. J Clin Oncol 2015;33:3137–43.CrossRefPubMedPubMedCentral Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. J Clin Oncol 2015;33:3137–43.CrossRefPubMedPubMedCentral
14.
go back to reference Kaplan CP, Livaudais-Toman J, Tice JA, Kerlikowske K, Gregorich SE, Perez-Stable EJ, Pasick RJ, Chen A, Quinn J, Karliner LS. A randomized, controlled trial to increase discussion of breast cancer in primary care. Cancer Epidemiol Biomark Prev 2014;23:1245–53.CrossRef Kaplan CP, Livaudais-Toman J, Tice JA, Kerlikowske K, Gregorich SE, Perez-Stable EJ, Pasick RJ, Chen A, Quinn J, Karliner LS. A randomized, controlled trial to increase discussion of breast cancer in primary care. Cancer Epidemiol Biomark Prev 2014;23:1245–53.CrossRef
15.
go back to reference Haas JS, Kaplan CP. The Divide Between Breast Density Notification Laws and Evidence-Based Guidelines for Breast Cancer Screening: Legislating Practice. JAMA Intern Med 2015;175:1439–40.CrossRefPubMedPubMedCentral Haas JS, Kaplan CP. The Divide Between Breast Density Notification Laws and Evidence-Based Guidelines for Breast Cancer Screening: Legislating Practice. JAMA Intern Med 2015;175:1439–40.CrossRefPubMedPubMedCentral
16.
go back to reference Rhodes DJ, Radecki Breitkopf C, Ziegenfuss JY, Jenkins SM, Vachon CM. Awareness of breast density and its impact on breast cancer detection and risk. J Clin Oncol Off J Am Soc Clin Oncol 2015;33:1143–50.CrossRef Rhodes DJ, Radecki Breitkopf C, Ziegenfuss JY, Jenkins SM, Vachon CM. Awareness of breast density and its impact on breast cancer detection and risk. J Clin Oncol Off J Am Soc Clin Oncol 2015;33:1143–50.CrossRef
17.
go back to reference Schonberg MA, Hamel MB, Davis RB, Griggs MC, Wee CC, Fagerlin A, Marcantonio ER. Development and evaluation of a decision aid on mammography screening for women 75 years and older. JAMA Intern Med 2014;174:417–24.CrossRefPubMedPubMedCentral Schonberg MA, Hamel MB, Davis RB, Griggs MC, Wee CC, Fagerlin A, Marcantonio ER. Development and evaluation of a decision aid on mammography screening for women 75 years and older. JAMA Intern Med 2014;174:417–24.CrossRefPubMedPubMedCentral
18.
go back to reference Haas JS, Baer HJ, Eibensteiner K, Klinger EV, St Hubert S, Getty G, Brawarsky P, Orav EJ, Onega T, Tosteson AN, Bates DW, Colditz G. A Cluster Randomized Trial of a Personalized Multi-Condition Risk Assessment in Primary Care. Am J Prev Med 2017;52:100–5.CrossRefPubMed Haas JS, Baer HJ, Eibensteiner K, Klinger EV, St Hubert S, Getty G, Brawarsky P, Orav EJ, Onega T, Tosteson AN, Bates DW, Colditz G. A Cluster Randomized Trial of a Personalized Multi-Condition Risk Assessment in Primary Care. Am J Prev Med 2017;52:100–5.CrossRefPubMed
19.
go back to reference Knerr S, Wernli KJ, Leppig K, Ehrlich K, Graham AL, Farrell D, Evans C, Luta G, Schwartz MD, O'Neill SC. A web-based personalized risk communication and decision-making tool for women with dense breasts: Design and methods of a randomized controlled trial within an integrated health care system. Contemp Clin Trials 2017;56:25–33.CrossRefPubMedPubMedCentral Knerr S, Wernli KJ, Leppig K, Ehrlich K, Graham AL, Farrell D, Evans C, Luta G, Schwartz MD, O'Neill SC. A web-based personalized risk communication and decision-making tool for women with dense breasts: Design and methods of a randomized controlled trial within an integrated health care system. Contemp Clin Trials 2017;56:25–33.CrossRefPubMedPubMedCentral
20.
go back to reference Moyer VA, for the US Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:698–708.PubMed Moyer VA, for the US Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:698–708.PubMed
Metadata
Title
Randomized Trial of Personalized Breast Density and Breast Cancer Risk Notification
Authors
Jennifer S. Haas, MD, MSc
Catherine S. Giess, MD
Kimberly A. Harris, MM
Julia Ansolabehere
Celia P. Kaplan, DrPh, MA
Publication date
01-04-2019
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 4/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-018-4622-4

Other articles of this Issue 4/2019

Journal of General Internal Medicine 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.